Package Leaflet: Information for the User
PRAVASTATIN TARBIS20 mgfilm-coated tablets
Read all of this leaflet carefully before you start takingthis medicine because it contains important information for you.
Pravastatin Tarbis 20 mg belongs to a group of medicines known as statins, which act by reducing blood lipid, cholesterol, and triglyceride levels.
Pravastatin Tarbis 20 mg is indicated, along with a suitable diet, in:
Do not take Pravastatin Tarbis 20 mg
Warnings and precautions
Consult your doctor or pharmacist before starting to take Pravastatin Tarbis 20 mg.
It is possible that moderate increases in liver transaminase levels may occur, which, in most cases, return to their initial level without the need to discontinue treatment.
Your doctor may recommend that you have blood tests to determine the condition of your muscles before starting treatment and during treatment, to consider starting, continuing, or discontinuing treatment.
Consult your doctor or pharmacist before taking Pravastatin Tarbis 20 mg if you:
Tell your doctor if you are taking other medicines that can also cause muscle disorders, such as:
While you are taking this medicine, your doctor will check if you have diabetes or are at risk of developing diabetes. This risk of diabetes increases if you have high sugar and fat levels in your blood, are overweight, and have high blood pressure.
Consult your doctor, even if any of the above circumstances have occurred to you at any time.
Use of Pravastatin Tarbis 20 mg with other medicines
Tell your doctor or pharmacist that you are using, have recently used, or may need to use any other medicine.
Certain medicines may interact with Pravastatin Tarbis 20 mg; in these cases, it may be necessary to change the dose or interrupt treatment with one of them.
It is essential that you inform your doctor if you are taking or have recently taken any of the following medicines:
Taking Pravastatin Tarbis 20 mg with food and drinks
Pravastatin Tarbis 20 mg can be taken with or without food.
Pravastatin Tarbis 20 mg should be administered with caution to patients who consume alcohol. If you regularly drink alcohol, consult your doctor.
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pravastatin Tarbis 20 mg should not be taken during pregnancy. If you become pregnant or think you may be pregnant, you should stop taking the treatment and inform your doctor as soon as possible.
Pravastatin Tarbis 20 mg should not be taken during breast-feeding as it passes into breast milk.
Driving and using machines
At normal doses, Pravastatin Tarbis 20 mg does not affect the ability to drive or use machines. However, if you notice symptoms of dizziness, do not drive or use machines until you know how the medicine affects you.
Pravastatin Tarbis 20 mg contains lactose.
If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
Follow exactly the administration instructions of this medicine given by your doctor. If you are unsure, consult your doctor or pharmacist again. Remember to take your medicine.
Your doctor will tell you the duration of your treatment with Pravastatin Tarbis 20 mg. Do not stop treatment before.
Pravastatin Tarbis 20 mg tablets are for oral administration.
The tablets should be swallowed with water and can be taken with or without food, preferably at night.
The recommended dose is between 10-40 mg once a day. Your doctor will establish the suitable dose for you and make the necessary adjustments based on your response to the medicine.
Combined treatment:patients treated with pravastatin and cyclosporin should start treatment with 20 mg of pravastatin once a day; your doctor will adjust the dose up to 40 mg. For patients treated with pravastatin and a bile acid sequestrant (e.g., colestyramine, colestipol), Pravastatin Tarbis 20 mg should be administered 1 hour before or 4 hours after the sequestrant.
Children and adolescents:the administration of pravastatin is not recommended for children under 18 years of age, as its efficacy and safety have not been established in this age group.
Elderly patients:no dose adjustment is necessary in these patients unless there are other risk factors.
Patients with renal or hepatic impairment:in patients with moderate or severe renal impairment or significant hepatic impairment, treatment should be initiated with a dose of 10 mg.
If you think the effect of Pravastatin Tarbis 20 mg is too strong or too weak, talk to your doctor or pharmacist.
If you take more Pravastatin Tarbis 20 mg than you should
If you have taken more Pravastatin Tarbis 20 mg than you should, contact your doctor or pharmacist or the nearest hospital.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 915 620 420, indicating the medicine and the amount ingested.
If you forget to take Pravastatin Tarbis 20 mg:
Do not take a double dose to make up for forgotten doses. Wait for the next dose.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, Pravastatin Tarbis 20 mg can cause side effects, although not everybody gets them.
Frequencies are defined as follows: very common (may affect more than 1 in 10 people); common (may affect up to 1 in 10 people); uncommon (may affect up to 1 in 100 people); rare (may affect up to 1 in 1,000 people); very rare (may affect up to 1 in 10,000 people); not known (cannot be estimated from the available data).
Immune system disorders:
Very rare: allergic reactions, angioedema (swelling of the arms, legs, face, lips, tongue, and/or throat), lupus-like syndrome (inflammation of the skin).
Nervous system disorders:
Uncommon: dizziness, headache, sleep disorders, insomnia.
Very rare: peripheral neuropathy, particularly when used for a prolonged period, and tingling sensation.
Not known: severe myasthenia (a disease that causes generalized muscle weakness that, in some cases, affects the muscles used for breathing).
Consult your doctor if you experience weakness in your arms or legs that worsens after periods of activity, double vision, or drooping eyelids, difficulty swallowing, or difficulty breathing.
Eye disorders:
Uncommon: vision disturbances (including blurred vision and double vision of objects).
Not known: ocular myasthenia (a disease that causes weakness of the eye muscles).
Gastrointestinal disorders:
Uncommon: indigestion/heartburn, abdominal pain, nausea, vomiting, constipation, diarrhea, gas.
Very rare: pancreatitis (inflammation of the pancreas).
Hepatobiliary disorders:
Very rare: jaundice (yellowing of the skin), hepatitis (inflammation of the liver), fulminant hepatic necrosis (destruction of liver cells).
Skin and subcutaneous tissue disorders:
Uncommon: itching, skin rash, blistering accompanied by itching, hair and scalp abnormalities (including hair loss).
Musculoskeletal and connective tissue disorders:
Very rare: rhabdomyolysis (destruction of muscle fibers), which may be associated with kidney disorders, myopathy (muscle disorders).
Tendon disorders, sometimes complicated by rupture.
Not known: constant muscle weakness.
Endocrine disorders:
Not known: diabetes. This is more likely if you have high sugar and fat levels in your blood, are overweight, and have high blood pressure. Your doctor will monitor you while you are taking this medicine.
Psychiatric disorders:
Unknown frequency: depression, nightmares, and memory loss.
Renal and urinary disorders:
Uncommon: changes in urine elimination (such as difficulty urinating, frequent urination, and increased urination at night).
Reproductive system and breast disorders:
Uncommon: sexual disorders.
General disorders:
Uncommon: fatigue.
Not known: isolated cases of interstitial lung disease, especially with prolonged treatment (see section 4.4).
The following adverse effects of special clinical interest have also been reported during clinical studies:
Musculoskeletal and connective tissue disorders:
Musculoskeletal pain, including joint pain, muscle cramps, muscle pain (very common), muscle weakness (common), and elevated creatine kinase levels (enzyme indicative of muscle disorder).
Hepatic disorders:
Elevations of serum transaminases (enzymes indicative of liver disease).
Reporting of side effects
If you experience any side effects, consult your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not store above 25°C.
Store in the original packaging to protect from moisture.
Expiry date
Do not use this medicine after the expiry date which is stated on the carton, after EXP. The expiry date is the last day of the month stated.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
COMPOSITION OF PRAVASTATIN TARBIS 20 MG
Appearance of the product and pack contents
Pravastatin Tarbis 20 mg is presented as light brown, scored tablets. Each pack contains 28 tablets.
Pravastatin Tarbis 10 mg film-coated tablets.
Pravastatin Tarbis 40 mg film-coated tablets.
Marketing authorization holder and manufacturer
Marketing authorization holder
Tarbis Farma, S.L.
Gran Vía Carlos III, 94
08028 Barcelona
Manufacturer
Lek Pharmaceutical Company D.D.
Verovskova, 57 (Ljubljana) – 1526 - Slovenia
or
Lek Pharmaceuticals d.d.
Trimlini, 2 D
9220 Lendava - Slovenia
Date of last revision of this leaflet: April 2023
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/